HHC
NKTR icon

Hutchin Hill Capital’s Nektar Therapeutics NKTR Stock Holding History

Hutchin Hill Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-17,267
Closed -$3.24M – 704
2015
Q2 		$3.24M Buy
+17,267
New +$2.97M 0.08% 218

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Hutchin Hill Capital's NKTR Position: Q3 2015 in Review

Hutchin Hill Capital sold out of Nektar Therapeutics (NKTR) in Q3 2015, closing a stake of 17,267 shares — an estimated $3.24M sold.

Hutchin Hill Capital first reported a position in NKTR in Q2 2015 and held it in 1 quarter. The position peaked at $3.24M in Q2 2015. 166 funds tracked by Wall St. Rank hold NKTR as of Q3 2015.

  • Hutchin Hill Capital reported no remaining Nektar Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Hutchin Hill Capital sold 17,267 Nektar Therapeutics shares in Q3 2015, an estimated $3.24M.
  • Hutchin Hill Capital first reported a position in Nektar Therapeutics in Q2 2015 and held it in 1 quarter.
  • Hutchin Hill Capital's Nektar Therapeutics position peaked at $3.24M in Q2 2015.
  • 166 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2015.

Based on Hutchin Hill Capital's 13F filing for Q3 2015, filed 16 Nov 2015.